Tyrosine kinase inhibitors trang 1 tải miễn phí từ TAILIEUCHUNG

"Tyrosine kinase inhibitors" trang 1 - tải miễn phí từ Tailieuchung

Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents

Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents

11 65 0

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors

11 40 0

STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers

STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers

14 73 0

Comparison of the efficacies of firstgeneration epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced nonsmall-cell lung cancer harboring EGFR mutations

Comparison of the efficacies of firstgeneration epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced nonsmall-cell lung cancer harboring EGFR mutations

7 69 0

Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: A case report

Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: A case report

6 32 1

Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: A systematic review and meta-analysis

Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: A systematic review and meta-analysis

9 29 1

Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma

Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma

4 48 1

Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: A report from population-based Lithuanian haematological disease registry 2000–2013

Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: A report from population-based Lithuanian haematological disease registry 2000–2013

10 24 1

Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma

Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma

13 63 1

Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: Long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors

Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: Long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors

12 19 1

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: Study protocol of the ABP trial

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: Study protocol of the ABP trial

10 36 1

Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement

Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement

12 64 1

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia

8 42 1

Finding the right BCR-ABL1 tyrosine kinase inhibitor: A case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib

Finding the right BCR-ABL1 tyrosine kinase inhibitor: A case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib

5 49 1

Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors

Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors

7 56 1

Case report: Small cell transformation and metastasis to the breast in a patient with lung adenocarcinoma following maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitors

Case report: Small cell transformation and metastasis to the breast in a patient with lung adenocarcinoma following maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitors

6 35 1

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

6 48 1

Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: Comparison with historical cohort using erlotinib

Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: Comparison with historical cohort using erlotinib

10 65 1

The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ

The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ

7 36 1

Detection and characterization of classical and “uncommon” exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing

Detection and characterization of classical and “uncommon” exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing

9 44 1

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.